Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

1 article from the last 30 days matching "pathology"

ResearchBIORXIVToday

Preprint: Granulin loss and TMEM106B risk converge on lysosomal C-terminal fragment pathology in frontotemporal dementia

Scientists are studying how two genes work together to cause frontotemporal dementia, a type of brain disease that affects thinking and behavior. One gene called GRN normally makes a protein that protects brain cells, but when it's broken, people can develop dementia. Another gene called TMEM106B can either increase or decrease the risk of getting sick. This research helps explain why some people with the broken GRN gene stay healthy their whole lives while others get dementia.

WHY IT MATTERSIf you or a family member carries a GRN mutation, understanding how TMEM106B variants modify your risk could eventually help doctors predict who will develop frontotemporal dementia and when, potentially enabling earlier monitoring or future preventive treatments.
Good to knowFrontotemporal dementiaFrontotemporal dementia with granulin mutationsRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases